In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

Novo Nordisk, the company that makes the weight loss drugs Ozempic and Wegovy, is abruptly ousting its chief executive, Lars Fruergaard Jørgensen, over concerns the firm is losing ground in the ...

Stocks closed solidly higher on Friday, pushing major indexes to big weekly gains for the third time in the last four weeks.

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

A growing number of users say Ozempic is rewiring their taste buds in ways they never saw coming. Many have complained about unexpected side effects like the Ozempic butt, the Ozempic mouth, and the ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...

For those preferring a drug-free approach to weight loss, research shows that certain nutrients and dietary strategies can naturally mimic the effects of semaglutides.

From marathon gym sessions and trendy detox teas to the latest GLP-1 injections, people will try just about anything to get ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...